Abstract
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:TNF as a Target of Inflammation in Rheumatoid Arthritis
Volume: 15 Issue: 2
Author(s): Hisashi Yamanaka
Affiliation:
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Abstract: Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Export Options
About this article
Cite this article as:
Yamanaka Hisashi, TNF as a Target of Inflammation in Rheumatoid Arthritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316121808
DOI https://dx.doi.org/10.2174/1871530315666150316121808 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property
Recent Patents on Inflammation & Allergy Drug Discovery Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19
Protein & Peptide Letters Evaluation of Biochemical Properties of Digestive Lipolytic Enzymes from the Marine Snail (Hexaplex trunculus)
The Natural Products Journal Targeting Bacterial Antioxidant Systems for Antibiotics Development
Current Medicinal Chemistry Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Knee Osteoarthritis and Exercise Adherence: A Review
Current Aging Science Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Phospholipase Cγ Signaling in Bone Marrow Stem Cell and Relevant Natural Compounds Therapy
Current Stem Cell Research & Therapy Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry Osmotically Regulated Flow of Flurbiprofen through In Situ Formed Asymmetric Membrane Capsule
Current Drug Delivery The Roles of Apoptosis in Wound Healing and Pulmonary Fibrosis
Drug Design Reviews - Online (Discontinued) The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View
Mini-Reviews in Medicinal Chemistry A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Towards Improved Therapeutic CORMs: Understanding the Reactivity of CORM-3 with Proteins
Current Medicinal Chemistry Editorial [Hot Topic:Platelets in Inflammation and Inflammatory Disorders Guest Editor: Armen Yuri Gasparyan ]
Inflammation & Allergy - Drug Targets (Discontinued) Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
Current Respiratory Medicine Reviews Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics